{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-314755","form_type":"8-K","ticker":null,"cik":"0001293971","company_name":"bluebird bio, Inc.","filed_at":"2022-12-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.039860+00:00","generated_at":"2026-06-20T21:48:26.019105+00:00","sec_items":["2.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"bluebird bio closes sale of rare pediatric disease PRV to argenx for $102M","bullets":["Completed sale of Rare Pediatric Disease Priority Review Voucher to argenx BV for $102M cash.","PRV awarded under FDA program for SKYSONA approval for cerebral adrenoleukodystrophy.","Transaction closed on Dec 29, 2022 after HSR waiting period expiration.","Terms consistent with previously disclosed Asset Purchase Agreement from Nov 29, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-314755","json":"https://secwatch.observer/filing/0001193125-22-314755.json","markdown":"https://secwatch.observer/filing/0001193125-22-314755.md","text":"https://secwatch.observer/filing/0001193125-22-314755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293971/000119312522314755/0001193125-22-314755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293971/000119312522314755/d413031d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T21:48:26.019105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c42c79a4364a8b45291a7ebefb833e34d644394","claim":"bluebird bio, Inc. completed a disposition involving argenx BV for $102.0 million in cash (closed 2022-12-29).","evidence_excerpt":"Report on Form 8-K filed with the Securities and Exchange Commission on November 30, 2022 (the “Prior 8-K”). Pursuant to the PRV Transfer Agreement, Buyer paid the Company $102.0 million in cash upon the closing of the Asset Sale. The foregoing description of the material terms of the PRV Transfer Agreement does not purport to be complete and is qualified in its","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312522314755/0001193125-22-314755-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"argenx BV"},{"label":"Consideration","value":"$102.0 million in cash"},{"label":"Closing","value":"2022-12-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}